Omicron-based COVID shots improve response | Inquirer News

Omicron-based COVID shots improve response vs that variant – Pfizer-BioNTech

/ 10:56 PM June 25, 2022

COVID-19 booster vaccine clinic in Lansdale. STORY: Omicron-based COVID shots improve response vs that variant – Pfizer-BioNTech

Doses of the Pfizer-BioNTech vaccine against the coronavirus disease (COVID-19) are pictured at a booster clinic for 12 to 17-year-olds in Lansdale, Pennsylvania, US, Jan. 9, 2022. (REUTERS/Hannah Beier)

NEW YORK — Pfizer Inc. and BioNTech SE said on Saturday that a booster dose of updated versions of their COVID-19 vaccine, modified specifically to combat the Omicron coronavirus variant, generated a higher immune response against that variant.

Advisors to the US Food and Drug Administration are scheduled to meet on Tuesday to discuss whether to update COVID-19 vaccines for the fall. The updated shots are likely to be redesigned to combat the Omicron variant of the coronavirus, experts say.

ADVERTISEMENT

Pfizer and BioNTech said that 30 and 60 microgram doses of a shot targeting just the BA.1 Omicron subvariant that was circulating last winter elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against that subvariant. A version of the shot that contained both the redesigned vaccine and their original vaccine elicited a 9.1 and 10.9-fold increase, they said.

FEATURED STORIES

The results were from a trial of 1,234 people aged 56 or older. The shots were well-tolerated in participants, the companies said.

They said that early laboratory studies suggest that both Omicron-modified candidates neutralize the Omicron BA.4 and BA.5 subvariants that have been circulating more recently, though to a lesser extent than they do for BA.1, with titers approximately 3-fold lower. The companies say they are continuing to collect data on how well the boosters perform versus the more recently circulating strains.

Moderna Inc has also made a redesigned vaccine targeting the BA.1 Omicron subvariant. The company said its updated vaccine worked well against more recent Omicron subvariants, and that it was moving forward with plans to ask regulators for approval.

RELATED STORIES

Chinese-made Omicron vaccine trials get going

Omicron less likely to cause long COVID – UK study

ADVERTISEMENT

Omicron BA.2.12.1 in PH: What you need to know

ATM
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: BioNTech SE, COVID-19 Omicron variant, Pfizer

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.